Pregabalin Capsule
Product Images NDC 71610-719

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-719). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 150 mg (71610 0719 30)

Label for Pregabalin 150 mg capsules, bottle containing 30 capsules, manufactured by Aphena Pharma Solutions - Tennessee, LLC. The label includes storage instructions, manufacturer details, NDC number 71610-0719-30, and warnings including that the drug may be habit forming and is for prescription use only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of Pregabalin, showing the molecular arrangement including an amino group (NH2) and a carboxylic acid group (CO2H) attached to a carbon backbone.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for different doses of Pregabalin and placebo. The graph includes four lines representing Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo, illustrating patient response levels across increasing pain improvement percentages.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline. Two lines represent Pregabalin 100 mg three times a day and placebo, showing more patients improved with Pregabalin across various pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin dosages of 75 mg, 150 mg, and 300 mg taken two times a day against placebo. The x-axis shows percent improvement in pain from baseline (0 to 100%), and the y-axis shows percent of patients improved (0 to 100%). Lines represent each Pregabalin dose and placebo performance.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and Placebo. Each group is represented with a distinct line style, showing higher improvement percentages for pregabalin doses compared to placebo.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows the higher percentage of patients improved with both Pregabalin doses compared to placebo across varying levels of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin 07)

This is a bar chart comparing responder rates (%) in two clinical studies labeled Study E1 and Study E3. The x-axis shows treatment groups including placebo and various doses of pregabalin (50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day) with dosing schedules BID or TID. The y-axis represents responder rate percentages ranging from 0% to 60%. Study E1 shows increased response rates with higher pregabalin doses from 14% placebo to 51% at 600 mg/day BID. Study E3 shows placebo at 9%, with pregabalin 300 mg/day BID at 43% and 600 mg/day TID at 49%.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph showing median percentage seizure reduction from baseline versus dose in mg/day for Pregabalin. Four studies are represented with different symbols indicating dosing frequency: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID. Significant p-values are noted for all data points compared to placebo (0 dose). The graph displays increasing seizure reduction with increasing Pregabalin dose up to 600 mg/day.*

FDA Label Image

Figure 9 (Pregabalin 09)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses of 600 mg, 450 mg, 300 mg daily, and placebo. The x-axis shows percent pain improvement ranging from >0 to 100, and the y-axis shows percent of patients improved from 0 to 100. Four lines represent different treatment groups, illustrating comparative patient response rates across increasing pain improvement percentages.*

FDA Label Image

Figure 10 (Pregabalin 10)

A Kaplan-Meier survival curve showing the estimated percentage of subjects without LTR over time in days, comparing Pregabalin (solid line) versus Placebo (dashed line). The y-axis represents the estimated percentage from 0% to 100%, and the x-axis represents days from 0 to 180. Pregabalin demonstrates a higher percentage of subjects without LTR over the study period compared to placebo.*

FDA Label Image

Figure 11 (Pregabalin 11)

A line graph showing the percent of subjects improved over time from baseline to Week 12 BOCF. The x-axis represents percent improved from baseline to Week 12 BOCF, ranging from 0 to 100, while the y-axis shows percent of subjects improved, also ranging from 0 to 100. Two lines are plotted: one solid for Pregabalin and one dashed for placebo, with the Pregabalin group showing a higher percent improvement compared to placebo.*

FDA Label Image

Figure 12 (Pregabalin 12)

A line graph depicting the percent of subjects improved from baseline to week 16 based on percent improvement. The x-axis represents percent improvement from baseline to week 16 BOCF, ranging from 0 to 100. The y-axis shows the percent of subjects improved, ranging from 0 to 80. Two curves are shown: one for Pregabalin and one for Placebo, illustrating treatment effects over the improvement range.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.